"One deal next year": Lee Seung-ju, CEO of Orum Therapeutics, what's his next move? [Bio Figures in Focus]
Predicted impact: Low
CEO interview on future deal goals; vague with no specific deal size disclosed.
Orum Therapeutics오름테라퓨틱
475830 · KOSDAQ · ₩475830 · 오름테라퓨틱
₩16,070▼ ₩40 (0.25%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −59.67%
- Market cap
- ₩350B
- Enterprise value
- ₩244B
- P/E
- 18.9×
- P/B
- 1.9×
- Dividend yield
- 0.0%
- ROE
- 10.0%
- Net margin
- 45,646.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−89.0% from the high
₩15,690Today: ₩15,800 – ₩16,850₩146,600
Returns
- 1W−1.0%
- 1M−35.7%
- 3M−63.3%
- 6M−82.4%
- YTD−86.6%
- 1Y−59.7%
- Volume today
- 134,927
- 0.4× the 20-day average
- Traded today
- ₩2.2B
- Listed shares
- 21,752,916
- EPS (12 months)
- ₩851
- Earnings yield 5.3%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 30 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only a headline, with no details on the deal or its effect on the company. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-36.7% over the last month; the price is below its 20-day average.
- News impactLow7 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Sep 22: sell ₩443M at the close (3.8% of 20-day average trading value)
On its 36 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 12.8% of trading value and pointed the same way 16 of 36 times.
- 2× KODEX KOSDAQ150 Leverage −₩423M
- -1× KODEX KOSDAQ150 Futures Inverse −₩11M
- 2× TIGER KOSDAQ150 Leverage −₩6.1M
- 2× RISE KOSDAQ150 Futures Leverage −₩2.3M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Futures and options
All stock futures →Futures (2026-11): 16,030
Basis −0.25% · implied rate −5.7%
Open interest 419 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Orum Therapeutics stock overview
Orum Therapeutics (오름테라퓨틱, KRX: 475830) is listed on KOSDAQ, in the Biotech & Pharma sector. Orum Therapeutics develops antibody-drug conjugates (ADCs) that deliver targeted protein degraders, using a proprietary platform it calls TPD², which combines ADC antibody targeting with targeted protein degradation. Its shares closed at ₩16,070 on Oct 27, 2026, down 0.25% on the day, giving it a market value of ₩350B.
Key facts
- Market cap
- ₩350B
- Sector
- Biotech & Pharma
- Latest price change
- −0.25%
- As of
- Oct 27, 2026
- Main business
- Orum Therapeutics develops antibody-drug conjugates (ADCs) that deliver targeted protein degraders, using a proprietary platform it calls TPD², which combines ADC antibody targeting with targeted protein degradation.
Quick answers about Orum Therapeutics
- What does Orum Therapeutics do?
- Orum Therapeutics develops antibody-drug conjugates (ADCs) that deliver targeted protein degraders, using a proprietary platform it calls TPD², which combines ADC antibody targeting with targeted protein degradation. Its lead programs deliver a GSPT1-degrading payload to cancer cells via antibodies against CD33 and CD123, targeting acute myeloid leukemia, myelodysplastic syndromes, other CD123-positive blood cancers, small cell lung cancer, and neuroendocrine tumors. One CD33-GSPT1 program (ORM-6151/BMS-986497) has been licensed to Bristol Myers Squibb, while other candidates remain in preclinical development.
- What is the market cap of Orum Therapeutics?
- The market capitalisation of Orum Therapeutics was ₩350B at the close on Oct 27, 2026.
- Who are the largest shareholders of Orum Therapeutics?
- According to the latest official filings, the largest reported holders are Lee Seung-ju (15.79%, as of Oct 21, 2026); Interbest (9.17%, as of Dec 2, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.26%, as of Jul 31, 2026).
- When is the next earnings report from Orum Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when Orum Therapeutics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Orum Therapeutics?
- Yes. The National Pension Service held 0.09% of Orum Therapeutics shares as of Dec 31, 2025.
Company profile
Orum Therapeutics develops antibody-drug conjugates (ADCs) that deliver targeted protein degraders, using a proprietary platform it calls TPD², which combines ADC antibody targeting with targeted protein degradation. Its lead programs deliver a GSPT1-degrading payload to cancer cells via antibodies against CD33 and CD123, targeting acute myeloid leukemia, myelodysplastic syndromes, other CD123-positive blood cancers, small cell lung cancer, and neuroendocrine tumors. One CD33-GSPT1 program (ORM-6151/BMS-986497) has been licensed to Bristol Myers Squibb, while other candidates remain in preclinical development.
Written by AI from the company's latest annual report.
- Korean name
- 오름테라퓨틱
- Sector
- Biotech & Pharma
- CEO
- 이승주
- Founded
- Aug 2016
- Listed
- Feb 2025
- Listed shares
- 21,752,916
- Fiscal year ends
- Month 12
- Website
- —
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Oryn Therapeutics CEO Lee Seung-joo buys ₩170M worth of treasury shares as stock falls
Predicted impact: Low
CEO buys ₩170M of treasury shares, small versus ₩353B market value.
Orum Therapeutics begins first patient dosing in Phase 1 trial of blood cancer treatment 'ORM-1153'
Predicted impact: Low· Actual: −11.2% vs sector, volume 0.3× normal (5 trading days)
Phase 1 first patient dosing; early-stage clinical step with no near-term revenue size.
Recent filings
See all- Results of Extraordinary Shareholders' MeetingOct 23, 2026
- Notice on Grant of Stock Purchase OptionsOct 23, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsOct 23, 2026
- Amended: Notice of shareholders' meetingOct 22, 2026
- 5%+ holding reportOct 21, 2026
Titles in Korean until English translations are added.
Also known as: Orum Therapeutics / 오름테라퓨틱 / 475830 / KRX:475830
Source: KRX statistical information